Review article: Hepatitis B and dialysis

被引:113
作者
Edey, Matthew [1 ]
Barraclough, Katherine [1 ]
Johnson, David W. [1 ]
机构
[1] Univ Queensland, Princess Alexandra Hosp, Dept Renal Med, Brisbane, Qld, Australia
关键词
end-stage renal failure; environmental transmission; haemodialysis; hepatitis B; treatment; vaccine; TENOFOVIR DISOPROXIL FUMARATE; PLACEBO-CONTROLLED TRIAL; CHRONIC-RENAL-FAILURE; LONG-TERM THERAPY; HEMODIALYSIS-PATIENTS; ADEFOVIR DIPIVOXIL; VIRUS INFECTION; VIRAL-HEPATITIS; PERITONEAL-DIALYSIS; IMMUNE-RESPONSE;
D O I
10.1111/j.1440-1797.2009.01268.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The incidence of hepatitis B virus (HBV) infection in dialysis populations has declined over recent decades, largely because of improvements in infection control and widespread implementation of HBV vaccination. Regardless, outbreaks of infection continue to occur in dialysis units, and prevalence rates remain unacceptably high. For a variety of reasons, dialysis patients are at increased risk of acquiring HBV. They also demonstrate different disease manifestations compared with healthy individuals and are more likely to progress to chronic carriage. This paper will review the epidemiology, modes of transmission and diagnosis of HBV in this population. Prevention and treatment will be discussed, with a specific focus on strategies to improve vaccination response, new therapeutic options and selection of patients for therapy.
引用
收藏
页码:137 / 145
页数:9
相关论文
共 110 条
[41]   National surveillance of dialysis-associated diseases in the United States, 2002 [J].
Finelli, L ;
Miller, JT ;
Tokars, JI ;
Alter, MJ ;
Arduino, MJ .
SEMINARS IN DIALYSIS, 2005, 18 (01) :52-61
[42]   HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients [J].
Fontaine, H ;
Thiers, V ;
Chrétien, Y ;
Zylberberg, H ;
Poupon, RE ;
Bréchot, C ;
Legendre, C ;
Kreis, H ;
Pol, S .
TRANSPLANTATION, 2000, 69 (10) :2090-2094
[43]   Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency [J].
Fontaine, HL ;
Vallet-Pichard, A ;
Chaix, ML ;
Currie, G ;
Serpaggi, J ;
Verkarre, V ;
Varaut, A ;
Morales, E ;
Nalpas, B ;
Brosgart, C ;
Pol, S .
TRANSPLANTATION, 2005, 80 (08) :1086-1092
[44]  
FUJIYAMA S, 1990, HEPATO-GASTROENTEROL, V37, P140
[45]   Management of chronic viral hepatitis before and after renal transplantation [J].
Gane, E ;
Pilmore, H .
TRANSPLANTATION, 2002, 74 (04) :427-437
[46]   Mechanisms of disease: Hepatitis B virus infection - Natural history and clinical consequences [J].
Ganem, D ;
Prince, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) :1118-1129
[47]   Viral Hepatitis in Elderly Haemodialysis Patients Current Prevention and Management Strategies [J].
Girndt, Matthias .
DRUGS & AGING, 2008, 25 (10) :823-840
[48]   Entecavir therapy for up to 96 weeks in patients with HBeAg-Positive chronic hepatitis B [J].
Gish, Robert G. ;
Lok, Anna S. ;
Chang, Ting-Tsung ;
De Man, Robert A. ;
Gadano, Adrian ;
Sollano, Jose ;
Han, Kwang-Hyub ;
Chao, You-Chen ;
Lee, Shou-Dong ;
Harris, Melissa ;
Yang, Joanna ;
Colonno, Richard ;
Brett-Smith, Helena .
GASTROENTEROLOGY, 2007, 133 (05) :1437-1444
[49]   IMMUNOGENICITY OF A HEPATITIS-B SUBUNIT VACCINE IN HEMODIALYSIS AND IN RENAL-TRANSPLANT RECIPIENTS [J].
GROB, PJ ;
BINSWANGER, U ;
ZARUBA, K ;
JOLLERJEMELKA, HI ;
SCHMID, M ;
HACKI, W ;
BLUMBERG, A ;
ABPLANALP, A ;
HERWIG, W ;
ISELIN, H ;
DESCOEUDRES, C .
ANTIVIRAL RESEARCH, 1983, 3 (01) :43-52
[50]  
Guan R, 1990, Ann Acad Med Singap, V19, P793